State Street shares fell approximately 7% by market open on October 14, 2026, after third-quarter revenue of $4.00 billion came in below the roughly $4.03 billion Wall Street expected. An investigation into potential securities law violations has been opened.

NEW YORK, Oct. 14, 2026 /PRNewswire/ -- Investors in State Street Corporation (NYSE: STT) watched their shares drop approximately 7% on October 14, 2026, after the Company reported third-quarter revenue of $4.00 billion, short of the roughly $4.03 billion analysts expected. If STT shares in your account lost value on the report, act now. Shareholders who lost money on State Street are encouraged to submit their losses for review today. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (888) SueWallSt.

Analysts had projected third-quarter revenue of roughly $4.03 billion. State Street reported approximately $4.00 billion -- a shortfall of about $30 million to $60 million against the consensus range. Fee revenue of approximately $3.14 billion particularly fell shy of the estimated $3.18 billion analysts had projected.

SueWallSt notifies investors of a pending investigation into whether State Street may not have adequately disclosed fee-revenue trends to investors before the October 14 report. The investigation also concerns whether shareholders who bought STT may have claims for potential securities law violations.

If you bought State Street stock and are now holding a loss, talk to an attorney about your STT losses or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the STT Investigation

Q: Who is eligible to participate in the STT investigation?A: Investors who purchased STT stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: How much did STT stock drop?A: Shares opened at about $161.90 on October 14, 2026, a decline of approximately $12.20, or 7%, from its closing price on October 13, 2026. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Which statements are being investigated as potentially misleading?A: The investigation concerns statements made before the October 14, 2026 third-quarter disclosure. The firm is examining whether those statements caused investors to purchase State Street securities at inflated prices.

Q: What do STT investors need to do right now?A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate?A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my STT shares? Can I still recover losses?A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought STT and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate?A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: What if I live outside the United States?A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (888) SueWallSt

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE SueWallSt.com

Share this article

The yield on CoreWeave's unsecured bonds reportedly reached 15% on October 13, 2026. The next day, the stock was dropping by nearly the same figure. The investigation concerns whether CoreWeave adequately disclosed the borrowing-cost risk tied to its debt-funded expansion.

NEW YORK, Oct. 14, 2026 /PRNewswire/ -- CoreWeave, Inc. (NASDAQ: CRWV) shares opened at $71.79, a decline of about 7.74% from the previous day's closing price of $77.81, as reports that the yield on the Company's unsecured bonds reportedly touched 15% developed. By midday, the stock price had fallen more than 15%. If you bought CRWV shares and lost money, you may have legal rights, and the investigation is underway now. Shareholders who suffered losses are encouraged to review your potential recovery options now . You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (888) SueWallSt.

This development follows CoreWeave's decision to increase its full-year CapEx guidance during its second quarter earnings call on August 11, 2026 from a range of $31 billion to $35 billion, to $35 billion to $39 billion, an increase of about 10.8% at the midpoint and significantly more than double the $14.9 billion it spent in 2025. Analysts have called the investment cycle "more pronounced than expected."

CoreWeave's buildout of data centers, GPUs and power capacity has been funded in large part with debt, and its interest expense has risen sharply. Before the bond selloff, CRWV had already fallen more than 45% below its 52-week high of $150.40. SueWallSt notifies shareholders of an investigation into potential securities law violations, including whether CoreWeave may not have adequately disclosed the borrowing-cost and refinancing risk tied to its expansion.

CoreWeave shareholders who lost money are encouraged to request a no-cost review of their CRWV losses or call (888) SueWallSt.

WHY SUEWALLST : SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the CRWV Investigation

Q: Who is eligible to participate in the CRWV investigation? A: Investors who purchased CRWV stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: How much did CRWV stock drop? A: Coreweave opened at $71.79 on October 14, 2026, down approximately $6.02 per share, or about 7.74% from its previous closing price. The stock continued to decline, reaching a more than 15% decline by midday as the market digested the news that CoreWeave's unsecured bonds reached 15%. Investors who purchased shares at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: Who is conducting the CRWV investigation? A: Levi & Korsinsky, LLP is investigating potential securities law violations on behalf of investors who purchased CRWV securities. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: What do CRWV investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery . No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my CRWV shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought CRWV and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (888) SueWallSt

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE SueWallSt.com

Share this article

Pilots in Seattle and Boise Demand Fair Contract After Years of Stalled Negotiations

SEATTLE, Oct. 14, 2026 /PRNewswire/ -- Nearly 650 pilots at Horizon Air, represented by Teamsters Local 1224, held an informational picket today in Seattle and Boise, calling on the airline to end years of delay tactics and agree to a fair contract that provides industry-standard compensation.

Teamsters pilots at Horizon have been negotiating for nearly four years for an agreement that addresses critical issues including wages, staffing and training shortages, and operational concerns that continue to impact both employees and the airline's future.

As a subsidiary of Alaska Air Group, Horizon pilots perform nearly the same amount of flying as their counterparts at Alaska Airlines. Despite those responsibilities, Horizon pilots' pay continues to fall behind industry standards due to the company's refusal to negotiate a fair agreement.

"Our pilots are the backbone of Horizon's operation," said Henry Simkins, Chair of Local 1224's Horizon Executive Council. "They continue to deliver safe and reliable service every day while management drags its feet on a contract that reflects their contribution and value. The same mismanagement has created operational challenges throughout the airline, and that dysfunction has become impossible to ignore in bargaining. Our members deserve better and they're tired of being told to wait."

In addition to the informational picket, Horizon pilots will conduct a vote of no confidence in Carlos Zendejas, Senior Vice President of Operations at Horizon.

Pilots at Horizon say chronic staffing shortages, inconsistent application of company policies and procedures, and a growing reliance on pilots to compensate for operational shortcomings are reasons for the vote. These issues have persisted throughout contract negotiations and have contributed to a significant erosion of trust in company leadership.

"Every day, Horizon pilots are expected to do more with less," said Jason Welch, a Horizon pilot and member of Local 1224. "We've watched these challenges persist for years, yet management refuses to address the issues that matter most to us. Enough is enough — it's time for the company to start delivering real solutions."

Teamsters Local 1224 represents aviation professionals throughout the United States, including flight crewmembers at ABX Air, Cape Air, Horizon Air, Omni Air International, and Silver Airways. Visit apa1224.org for more information.

Contact:

Lena Melentijevic, (347) 208-2279

LMelentijevic@teamster.org

SOURCE Teamsters Local 1224

Share this article

- 80% of surveyed executives in EMEA say an AI-related incident reached their board or C-suite in the past year, with only 40% changing AI governance policy or frameworks in response.

- 75% of respondents expect AI agents to have some level of autonomy with respect to decisions by 2027, yet only 37% say their governance is designed to scale with agentic AI deployment.

- When surveyed organizations want to deploy AI faster than governance and compliance frameworks are prepared for, nearly 60 percent (56%) continue within agreed risk limits while governance adapts; a third (33%) delay deployment until governance is ready.

- Only 37% of respondents have a formal, board-reviewed quantification of the financial risks created by gaps in their AI governance.

LONDON, Oct. 14, 2026 /PRNewswire/ -- New research by IBM (NYSE: IBM) finds that AI-related incidents are reaching boardrooms across Europe and the Middle East among the organizations surveyed, but governance capabilities and risk accountability are not keeping pace with adoption of the technology.

Eight in ten executives surveyed say an AI-related incident – including an agent failure, data exposure, AI-driven decision error, or AI security breach – reached their board or C-suite in the past year. Yet fewer than half (40%) of those organizations cite a change to AI governance policy or framework in response.

When the pace of deploying AI outstrips governance and compliance frameworks readiness, rather than pause while governance adapts, the majority (56%) of executives surveyed report pressing ahead within agreed risk limits. Just a third delay deployment entirely until their governance is ready.

The survey, of more than 3,200 senior executives at organizations across eight countries in Europe and the Middle East, suggests governance policies will be tested further as AI agents take on more autonomous work. Thirty-five percent of respondents say they are running agentic AI in production today, yet three-quarters expect AI agents to have some level of autonomy towards decisions by 2027. Only 37% say their current governance system is designed to scale with agentic AI deployment.

Ana Paula Assis, IBM Senior Vice President and Chair, EMEA and APAC, said: "The AI debate has moved from adoption to governance and accountability. As organizations progress from AI assistants to autonomous agents, governance can no longer be treated as a compliance exercise. It has become a business requirement and value enabler.

The enterprises that can scale AI with accountability and trust will be postitioned to realize business value. That means governance must be built into how agents operate, with clear boundaries on what they can do, clear ownership when things go wrong, and controls that work in real-time."

Accountability & liability gap

Nearly all executives (98%) surveyed have formally assigned responsibility for AI risk at board level, including 26% with a dedicated board-level AI committee. Yet the research found no clear consensus on accountability for adverse outcomes from AI agents. An organization's CIO or CTO was the most frequently cited role with assigned responsibility for adverse outcomes from AI agents, selected by just 17% of all respondents.

Respondents' views on legal liability when an AI system causes significant harm were also divided: 20% say it should be shared proportionally between deployer and vendor, 19% say there should be a regulatory framework that does not yet adequately exist, and 14% say it should sit with the AI vendor or technology provider.

To manage increasingly autonomous AI agents making decisions without human approval at each step by 2027, executives expect to need formal legal or contractual frameworks defining AI vendor liability for agent failures (33%), defined human escalation thresholds (32%), real-time monitoring and audit trails of agent decisions and actions (30%) and the ability to immediately halt agent activity across the enterprise (29%).

Other key findings include:

- Measurement of financial risk exposure less established than board ownership: More than half (54%) of surveyed executives govern generative AI tools and agentic AI systems as distinct risk categories with separate governance frameworks and a further 38% apply the same core framework, but with additional controls to agentic AI. Measuring financial exposure from gaps in AI governance is less advanced: only 37% have a formal, board-reviewed quantification of the financial risk created by gaps in their AI governance.

- Supply chain risk: 54% of all respondents acknowledge gaps or limitations in how their governance framework covers the AI systems and models used by key vendors, technology partners and supply chain participants. Only 21% continuously monitor third-party AI risk and 13% apply independent assurance or certification requirements.

- Regulation shapes the pace regionally: In the EU, 41% of surveyed executives are accelerating governance investment ahead of the EU AI Act's high-risk obligations in December 2027, and a further 35% are on track with structured compliance plans. In the UK, sector regulator expectations are the most cited driver of AI governance investment (27%), while in Saudi Arabia and the UAE, national AI strategy requirements lead (61%).

Study methodology

The research was conducted by Censuswide on behalf of IBM among 3,221 executive management respondents, including C-level, at organizations with 1,000 or more employees in the UK, France, Germany, Italy, Spain, the Netherlands, Saudi Arabia and the UAE. The data was collected between 14 and 24 September 2026.

About IBM

IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM's long-standing commitment to trust, transparency, responsibility, inclusivity, and service. Visit www.ibm.com for more information.

Media contact: 

Gregor Hastings

IBM EMEA Communications

[email protected]

SOURCE IBM

Share this article

Five-year collaboration framework aims to advance point-of-care diagnostics, clinical performance evaluation, and precision-medicine applications

LAS VEGAS and TORONTO, Oct. 14, 2026 /PRNewswire/ -- PurMinds Enterprises, Inc. (formerly Pacific Software, Inc.) (OTC: PFSF) ("PurMinds" or the "Company") today announced the signing of a collaboration agreement with SpectroChip Inc. ("SpectroChip"), a Taiwan-based developer of photonic-chip sensing and portable testing technologies, and Kaohsiung Municipal Siaogang Hospital ("Siaogang Hospital"), operated by Kaohsiung Medical University, to support teaching, research, and clinical validation of point-of-care (POC) diagnostic technologies and testing solutions.

The collaboration brings together SpectroChip's photonic chip-based portable testing technology, PurMinds' SwiftLabTM Platform and precision-medicine solutions, and Siaogang Hospital's clinical research capabilities. The parties intend to establish the joint "PurMinds / SpectroChip Global Clinical Validation Testing Center" for teaching, research, and clinical-validation activities, as a framework for evaluating diagnostic performance, assessing testing workflows, and advancing research into continuously improved POC performance, subject to review by an institutional review board (IRB), institutional approvals and applicable regulatory requirements.

Connecting diagnostic technology with clinical research

PurMinds' SwiftLabTM Platform is built around a full-spectrum laboratory-grade spectrometer shrunk onto a single, highly advanced photonic chip and housed inside the SpectroCision™ SPU-D100, a portable reader small enough to carry anywhere. The platform is designed to turn a low-cost lateral-flow cassette from a faint yes-or-no line into a lab-grade quantitative result in five minutes or less, in clinics, pharmacies, community health centers, and at the patient's bedside. Clinical research and performance evaluation are important steps in assessing how diagnostic technologies and testing solutions perform in intended-use settings.

Under the collaboration, the parties will contribute complementary capabilities:

- PurMinds will lead the precision-medicine applications, clinical research collaboration, and access to international research and industry resources in its overall global commercialization strategy.

- SpectroChip will provide its photonic chip-based testing technology, together with technical documentation, training, and related support.

- Siaogang Hospital will provide an institutional setting for approved teaching, research, and clinical-validation activities, including research design, performance evaluation, testing-workflow assessment, and talent development.

Specific research projects will be established through separate written arrangements defining their scope, responsibilities, timelines, funding, and deliverables. Activities involving human participants, specimens, personal data, or medical-device clinical studies will proceed in accordance with applicable ethical, regulatory, and institutional requirements. The designation does not represent the establishment of a separate legal entity or dedicated physical facility.

By connecting technology development with institutional research capabilities, the collaboration aims to create a foundation for evaluating diagnostic applications and supporting PurMinds' development and commercialization activities.

Research and education support

Under the collaboration framework, SpectroChip has committed to providing Siaogang Hospital with NT$3 million (about US$94,000) in teaching and research funding over five years, generally at NT$600,000 per year, subject to the applicable agreement and institutional procedures. The funding is intended to support approved educational and research activities, which may include research consumables, testing, equipment maintenance, data analysis, research personnel, training, and academic exchange. The collaboration framework preserves the hospital's independence in its professional, clinical, research, and procurement decisions.

"This collaboration brings together SpectroChip's cutting-edge photonic chip technology, Siaogang Hospital's clinical research environment and PurMinds' precision-medicine platform and commercialization strategy," said Janet Qi, Founder and Chief Executive Officer of PurMinds. "Given the full-spectrum spectrometry embedded in our platform and its potential to develop an extended catalog of testing items, our vision is to connect with clinically relevant testing applications and the research needed to evaluate them."

"For over two decades, our team has worked to miniaturize spectrometer technology and make quantitative analysis possible through our proprietary photonic chip technology. This collaboration with PurMinds and Siaogang Hospital represents an important opportunity to bring our technology into a structured clinical research environment, where diagnostic performance and testing workflows can be systematically evaluated," said Dr. Cheng-Hao (Kevin) Ko, founder of SpectroChip and inventor of the SwiftLab Platform.

"Collaboration between healthcare institutions, technology developers, and market integrators is important to the responsible evaluation of emerging diagnostic technologies. We look forward to supporting appropriate teaching and research activities, evaluating diagnostic performance under approved study protocols, and contributing clinical perspectives to the development of point-of-care testing. All research activities will be conducted in accordance with applicable ethical, institutional, and regulatory requirements," said Chih-Hsing Hung, MD, PhD, Dean of Kaohsiung Municipal Siaogang Hospital.

About PurMinds Enterprises, Inc.

PurMinds Enterprises, Inc. (OTC: PFSF) exists to close the gap between precise answers from a central laboratory, which arrive days after the patient has gone home, and fast answers from rapid tests, which offer a single faint "yes or no" line and nothing more. At the heart of its SwiftLab™ Platform is a full-spectrum, laboratory-grade spectrometer shrunk onto a photonic chip and housed inside the SpectroCision™ SPU-D100, a fully portable reader small enough to carry anywhere without the need for recalibration. The platform is designed to turn a low-cost lateral-flow cassette from a faint yes-or-no line into a quantitative result in five minutes or less. That capability stands on 17 peer-reviewed papers, 15 granted patents, and a trade-secret manufacturing process refined over 20 years.

One reader delivers every use case: comprehensive blood testing, veterinary diagnostics, roadside drug intoxication screening, specialized multiplex panels, and pathogen testing, all run on the same SpectroCision reader. Only the low-cost test cassette changes. Clinical uses are subject to regulatory clearance in each market. PurMinds holds an exclusive license to the SwiftLab Platform for the health and safety fields worldwide.

PurMinds began with a single ambition: to treat the brain. A company that means to treat the brain must be able to measure disease progression and therapeutic intervention, repeatedly, cheaply, and wherever the patient is, and that need brought PurMinds and SpectroChip together to build a quantitative point-of-care neurology panel. PurMinds holds its two drug candidates in a wholly owned subsidiary, PurQuest™ Therapeutics: PUR102, a botanical psilocybin, and PUR501, a preclinical non-hallucinogenic neuroplastogen.

The SpectroCision reader and PurMinds cassettes have not been cleared or approved by the United States Food and Drug Administration or licensed by Health Canada and are not available for clinical use in the United States or Canada.

For more information, visit www.purminds.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. These statements include, but are not limited to, statements concerning the collaboration among PurMinds, SpectroChip, and Siaogang Hospital; anticipated research, testing, and clinical-validation activities; the potential applications of point-of-care diagnostic technologies; the development and commercialization of diagnostic products; and the Company's business strategy.

Forward-looking statements are based on current expectations, assumptions, and estimates and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks include the ability to implement planned research activities, obtain required institutional and ethics approvals, meet regulatory requirements, demonstrate product performance, secure resources, and establish commercial relationships; that regulators may not clear, waive, or license the Company's products, or may do so later or with narrower claims than expected; that the Company depends on licenses and collaborations with third parties that could be lost or restricted; that the Company requires additional capital and may not obtain it on acceptable terms; and that the Company is a former shell company with a limited operating history, has not yet published audited financial statements, and has a small public float; as well as competition and general economic and market conditions.

The collaboration does not guarantee any particular research outcome, regulatory authorization, product commercialization, or financial result. No assurance can be given that the parties will complete planned activities within anticipated timelines or achieve their intended objectives. Readers should not place undue reliance on forward-looking statements. Except as required by applicable law, PurMinds undertakes no obligation to update forward-looking statements following the date of this release. This press release is not an offer to sell or a solicitation of an offer to buy any security.

SOURCE PurMinds Enterprises, Inc.

Share this article

A new large scale clinical trial provides the strongest evidence yet that CGMs can significantly improve blood sugar in people with type 2 diabetes not using insulin

AURORA, Colo., Oct. 14, 2026 /PRNewswire/ -- Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings from new research published in the New England Journal of Medicine.

The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

CGMs use a small sensor worn on the body to continuously track glucose levels throughout the day and night. This allows patients to see how their blood sugar responds to food, physical activity and other daily habits, potentially helping them make more informed decisions about managing their diabetes.

"An estimated 20 million adults in the United States have type 2 diabetes and do not take insulin, and despite advances in treatment, many still still do not reach glycemic targets," said first author Tamara Oser, MD, professor in the University of Colorado Anschutz Department of Family Medicine. "Over time, elevated blood sugar can increase the risk of serious health complications, including heart disease, kidney disease and vision loss, so it's important we continue to improve care for everyone with diabetes."

Tamara and her co-authors also found another significant finding: CGM users experienced significantly greater improvements in A1c, a measure of average blood sugar over approximately three months. The difference between the groups was 0.9 percentage points, greatly exceeding the threshold generally considered clinically meaningful.

Largest clinical trial of its kind

The study included 283 adults across 22 U.S. primary care practices who were followed for 26 weeks. It's the first large-scale, multicenter randomized controlled trial to evaluate the effectiveness and safety of CGM in adults with type 2 diabetes who do not take insulin.

Unlike smaller previous studies, this trial exclusively enrolled patients receiving diabetes care through primary care practices, where most Americans with type 2 diabetes are treated. This approach makes the findings particularly relevant to everyday clinical care.

Reshaping treatment recommendations

The findings provide some of the strongest evidence yet for this population, which has historically been underresearched.

Currently, the American Diabetes Association's Standards of Care cite Level A evidence, the highest rating supported by rigorous clinical research, for CGM use in patients receiving insulin. However, recommendations for people with diabetes who don't take insulin are supported by Level C evidence, reflecting more limited research.

The researchers hope these new findings could help close that gap by providing robust clinical evidence that CGMs improve blood sugar in this population.

"We hope this research will help strengthen national diabetes care guidelines and expand insurance coverage, making this technology more accessible to the millions of patients who could benefit from it," said Oser, who is also founder and director of the Primary Care Diabetes Lab at CU Anschutz.

For now, the authors suggest people with type 2 diabetes who don't take insulin should discuss the use of GCMs with their primary care providers as part of their diabetes management.

About the University of Colorado Anschutz

The University of Colorado Anschutz is a world-class academic medical campus leading transformative advances in science, medicine, education and patient care. The campus includes the University of Colorado's health professional schools, more than 60 centers and institutes, and two nationally ranked independent hospitals - UCHealth University of Colorado Hospital and Children's Hospital Colorado - which see nearly three million adult and pediatric patient visits each year. Innovative, interconnected and highly collaborative, CU Anschutz delivers life-changing treatments, exceptional patient care and top-tier professional training. The campus conducts world-renowned research supported by $890 million in funding, including $762 million in sponsored awards and $128 million in philanthropic gifts for research.

Find the latest CU Anschutz news here.

SOURCE University of Colorado Anschutz

Share this article

Community Healthcare Trust Announces Third Quarter Earnings Release Date And Conference Call

FRANKLIN, Tenn., Oct. 14, 2026 /PRNewswire/ -- Community Healthcare Trust Incorporated (NYSE: CHCT) today announced that on Tuesday evening, November 3, 2026, after the market closes, it will report results for the third quarter of 2026.

On November 4, 2026, at 9:00 a.m. Central Time, Community Healthcare Trust will hold a conference call to discuss earnings results, quarterly activities, general operations of the Company and industry trends. Simultaneously, a webcast of the conference call will be available to interested parties via an Internet link at www.chct.reit under the Investor Relations section. A webcast replay will be available following the call at the same Internet site address.

Conference Call Details

Domestic Dial-In Number: 1-888-347-1332

International Dial-In Number: 1-412-902-4278

Canada Toll Free: 1-855-669-9657

Replay Conference Call Details

Domestic & Canada Replay Number: 1-855-669-9658

International Replay Number: 1-412-317-0088

Conference ID: 9573519

About Community Healthcare Trust Incorporated

Community Healthcare Trust Incorporated (the "Company") is a real estate investment trust that focuses on owning income-producing real estate properties associated primarily with the delivery of outpatient healthcare services in our target sub-markets throughout the United States. As of June 30, 2026, the Company had investments of approximately $1.2 billion in 197 real estate properties (including one property with sales-type leases). The properties are located in 36 states, totaling approximately 4.5 million square feet in the aggregate.

Cautionary Note Regarding Forward-Looking Statements

In addition to the historical information contained within, the matters discussed in this press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identifiable by use of forward-looking terminology such as "believes", "expects", "may", "will," "should", "seeks", "approximately", "intends", "plans", "estimates", "anticipates" or other similar words or expressions, including the negative thereof. Forward-looking statements are based on certain assumptions and can include future expectations, future plans and strategies, financial and operating projections or other forward-looking information. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management. Because forward-looking statements relate to future events, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the control of Community Healthcare Trust Incorporated (the "Company"). Thus, the Company's actual results and financial condition may differ materially from those indicated in such forward-looking statements. Some factors that might cause such a difference include the following: general volatility of the capital markets and the market price of the Company's common stock, changes in the Company's business strategy, availability, terms and deployment of capital, changes in the real estate industry in general, interest rates or the general economy, adverse developments related to the healthcare industry, changes in governmental regulations, the degree and nature of the Company's competition, the ability to consummate acquisitions under contract, catastrophic or extreme weather and other natural events and the physical effects of climate change, the occurrence of cyber incidents, effects on global and national markets as well as businesses resulting from increased inflation, changes in interest rates, supply chain disruptions, labor conditions, prolonged government shutdown or budgetary reductions or impasses, tariffs and global trade tensions, and/or international conflicts (including the conflicts in the Ukraine and in the Middle East), and the other factors described in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and the Company's other filings with the Securities and Exchange Commission from time to time. Readers are therefore cautioned not to place undue reliance on the forward-looking statements contained herein which speak only as of the date hereof. The Company intends these forward-looking statements to speak only as of the time of this press release and undertakes no obligation to update forward-looking statements, whether as a result of new information, future developments, or otherwise, except as may be required by law.

CONTACT: Bill Monroe, 615-771-3052

SOURCE Community Healthcare Trust Incorporated

Share this article

President and CEO Thayne Shaffer to retire on March 1, 2027, after 38 years of service.

RIVERDALE, Utah, Oct. 14, 2026 /PRNewswire/ -- The America First Credit Union Board of Directors announced today that Missy Key has been selected to be the credit union's next President and Chief Executive Officer, effective March 1, 2027. She will succeed Thayne Shaffer, who plans to retire after 38 years of dedicated service to America First's members and employees.

"Missy is a strong, insightful and decisive executive who leads with vision and compassion," said Linda Carver, Chair of America First's Board of Directors. "Her 38 years of service at America First have prepared her well for this moment, and our members, employees and community partners are in good hands."

Key's appointment follows a milestone year for America First, including mergers with Meadows Bank and Greater Nevada Credit Union and growing to nearly 1.7 million members.

"America First has tremendous momentum, and Missy will carry forward that legacy of service and success," Shaffer said. "It has been an honor to work with her and so many other talented people at America First."

Shaffer became President and CEO in 2021. During his almost six-year tenure, America First achieved record asset and membership growth, weathered a pandemic and recession, completed three mergers and acquisitions, and launched a new digital banking system.

"Thayne's achievements as CEO speak for themselves, but his impact extends far beyond numbers," Carver said. "He has led with humility, transparency and an unwavering member-first focus. We are grateful for his remarkable service and wish him all the best in retirement."

Key will become the sixth President and CEO in America First's history.

"I am honored and excited by this opportunity," Key said. "I am grateful to have worked with Thayne for many years and appreciate the exemplary leadership he provided. I look forward to working with our Board and talented teams to continue building on our foundational values of serving members and strengthening the communities we serve."

Key's 38 years of service at America First include progressive leadership roles in accounting and finance, most recently serving as executive vice president and chief financial officer. Throughout her tenure, she has developed a deep understanding of America First's operations, its members and the communities it serves. As CFO, she has played an integral role in strengthening America First's financial position and working alongside the executive leadership team to shape and advance the credit union's strategic direction.

About America First Credit Union

Founded in 1939, America First has grown into one of the strongest and most progressive credit unions in the country. AFCU has more than $27 billion in assets and 135 branch locations across Arizona, California, Idaho, Nevada, New Mexico and Utah, serving more than 1.6 million members. America First is dedicated to helping members achieve their financial goals while building stronger communities.

SOURCE America First Credit Union

Share this article

HELI-D flew over the Hudson River near Chelsea Piers and the Statue of Liberty during the DPAA Global Video Everywhere Summit, followed by an evening flight showcasing Byron Allen's media content

NEW YORK, Oct. 14, 2026 /PRNewswire/ -- HELI-D, the company behind the world's largest flying digital screen, made its New York City debut on October 13 with two flights introducing a new form of aerial digital advertising to one of the world's largest media markets. The debut featured an afternoon flight in partnership with the Digital Place Based Advertising Association (DPAA) during its annual Global Video Everywhere Summit, followed by an evening flight showcasing content from media mogul Byron Allen's Allen Media Group as part of a newly secured partnership.

The afternoon flight took place between 1:00 PM and 1:45 PM ET, coinciding with the Summit's lunch break. Launching from Newport Helistop in New Jersey, HELI-D flew along the Hudson River toward Chelsea Piers, where Summit attendees and New Yorkers had an opportunity to see the massive digital screen in action. The aircraft then headed south toward the Statue of Liberty, bringing the display to one of the city's most recognizable landmarks.

HELI-D returned to the skies later that evening for a second flight featuring content from Byron Allen's Allen Media Group. The new agreement marks a significant step in HELI-D's entry into the U.S. advertising market, bringing together its aerial digital display technology and one of the country's prominent media entrepreneurs.

Unlike traditional billboards fixed to buildings or roadside structures, HELI-D's technology takes digital out-of-home advertising into the sky, creating a mobile, large-scale display capable of bringing brand messages directly to high-visibility locations, major events and large audiences.

"New York City is one of the most important advertising markets in the world, and there's no better place to demonstrate what's possible when digital advertising takes to the skies," said Simon Powell, Co-Founder and CEO of HELI-D. "Launching with DPAA and The Ad Council, and now working with Byron Allen and his media company, makes this an incredibly exciting debut for us. These partnerships demonstrate the potential of our technology to bring major brands and media content to audiences in an entirely new way."

The New York debut coincided with the DPAA Global Video Everywhere Summit, which brought together leaders from across the advertising, media and digital out-of-home industries. As a new media partner of DPAA and The Ad Council, HELI-D featured content from both organizations during the afternoon flight, demonstrating how its aerial display can be used for commercial advertising, public awareness campaigns and large-scale brand activations.

With two flights marking its New York City debut and new partnerships spanning the advertising and media industries, HELI-D is positioning its technology as a new addition to the digital out-of-home advertising landscape, offering brands the ability to deliver dynamic content above some of the world's most recognizable destinations and major events.

About HELI-D

HELI-D is a global leader in aerial digital media, redefining out-of-home advertising through high-impact, data-driven activations in the sky. Combining advanced aviation engineering with the world's brightest LED display systems, HELI-D transforms airspace into a programmable, measurable communications platform. With operations spanning UAE, Australia, and now the United States, the company partners with major brands, including Microsoft, TAB, and Netflix, to deliver record-setting campaigns that turn attention into action. HELI-D maintains a perfect safety record and offsets ten times its operational carbon emissions through verified sustainability programs.

About Remarkable Media Group

Remarkable Media Group is a global experiential media innovator, specializing in aerial advertising, immersive brand activations and next-level outdoor experiences. With operations across multiple continents, the company transforms sky and space into impactful platforms. From ultra-large-format helicopter-towed banners, drone-banner fleets and sky-typing messages, to night-time video helicopter banners and parachute-deployed product sampling. Whether creating world-first aerial installations or record-breaking brand moments, Remarkable Media Group partners with agencies and forward-thinking brands to amplify impact, tell bold stories and capture attention in the world's most visible skies. To learn more, visit www.remarkablemedia.com

Contact:

Rubenstein PR

Stephen Francy

212-805-3017

[email protected]

SOURCE Remarkable Media

Share this article

J&T Express Average Daily Parcel Volume Reaches 104.2 Million in Q3 2026; Exceeds 100 Million for Second Consecutive Quarter

China Parcel Volume Up 15.3% YoY; Other Markets Parcel Volume Up 159.5% YoY

HONG KONG, Oct. 14, 2026 /PRNewswire/ -- J&T Global Express Limited (01519.HK), a global logistics service provider, today announced its business update and operating metrics for the third quarter ended 30 September 2026. During the period, the Company's global parcel volume reached 9.58 billion, up 24.8% YoY, with average daily parcel volume reaching 104.2 million and exceeding 100 million for the second consecutive quarter. In the first nine months of 2026, the Company's global parcel volume reached 27.09 billion, up 25.0% YoY, with average daily parcel volume reaching 99.2 million. The Company's overall business momentum continued to strengthen, with its leading position in Southeast Asia maintained, robust growth recorded in Other Markets and growth in China rising to its highest level of the year.

In Southeast Asia, J&T Express further consolidated its market leadership and continued to deliver rapid growth in the third quarter, with parcel volume reaching 2.89 billion, up 44.5% YoY, and average daily parcel volume reaching 31.4 million. Parcel volume for the first nine months reached 8.41 billion, up 61.0% YoY. The Company continued to enhance its regional network capacity and fulfillment capabilities, promote automation upgrades across its outlets, and further increase automation levels. As of September 30, 2026, the number of sorting centers in Southeast Asia had increased by 10 from the end of 2025 to 131, the number of line-haul vehicles had increased by approximately 100 to 5,900, and the number of automated sorting lines had increased by 17 to 81, supporting the region's continued business growth.

In China, J&T Express proactively adapted to industry trends and deepened its engagement with diversified customer groups, with a focus on enhancing its service capabilities for customers in key categories such as apparel, beauty products and 3C electronics, as well as specialized segments including specialty agricultural products and fruit. In the third quarter, parcel volume in China reached 6.43 billion, with average daily parcel volume reaching 69.9 million, up 15.3% YoY, marking a quarter-by-quarter acceleration in growth. Parcel volume for the first nine months reached 18.04 billion, up 11.5% YoY. As of September 30, 2026, the number of line-haul vehicles in China had increased by approximately 500 from the end of 2025 to 7,700, including an increase of approximately 300 self-owned line-haul vehicles to 5,600, further strengthening the Company's network transportation capabilities.

In Other Markets, parcel volume reached 270.8 million in the third quarter, up 159.5% YoY, with average daily parcel volume reaching 2.9 million as the YoY growth rate continued to accelerate. Parcel volume for the first nine months reached 635.8 million, up 135.2% YoY. The Company continued to seize e-commerce development and cross-border logistics opportunities in regions such as Latin America and the Middle East, deepening cooperation with global e-commerce and short-video livestreaming platforms including TikTok, SHEIN, Temu, Kwai and AliExpress, as well as local e-commerce platforms such as Mercado Libre, to further expand its business opportunities in emerging markets.

As its global business continued to expand, J&T Express further strengthened its global network. As of September 30, 2026, the Company's global network comprised 20,300 outlets, an increase of approximately 1,000 from the end of 2025; 292 sorting centers, an increase of 46; and 457 automated sorting lines, an increase of 44. Going forward, J&T Express will continue to enhance its network capabilities, fulfillment efficiency and service quality, deepen localized operations in line with the development stage of each market, and advance AI applications, automation and digital capabilities to support the long-term, steady growth of its global business.

SOURCE J&T Global Express Limited

Share this article